= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Piga

MSACL 2018 EU Abstract

Topic: Proteomics

Podium Presentation in the Ether on Thursday at 9:20 (Chair: Éva Hunyadi-Gulyás)

Progress in Clinical Applications for the MALDI-Imaging Analysis of Thyroid Biopsies: Evaluation of Proteomic Stability in Preservative Solutions

Isabella Piga (Presenter)
University of Milano-Bicocca

Presenter Bio(s): I obtained a bachelor degree in Chemistry from the University of Cagliari. The bachelor internship sparked an interest in analytical sciences and resulted in the following of the analytical chemistry master program at the University of Pisa.
I decided to continue my academic career and I have attended the PhD School in Biochemistry and Molecular Biology at the University of Siena. As part of the PhD program, I have worked at the Center for Proteomics and Metabolomics in the Mass Spectrometry Imaging group, LUMC, the Netherlands.
I am currently a Post-Doc at the University of Milano-Bicocca and my work is mostly focus on mass spectrometry imaging proteomics and clinical application. My main project is focused on the MALDI-Imaging analysis of thyroid fine needle aspiration biopsies and the classification of the thyroid nodule lesions.

Authors: Isabella Piga (1,2), Giulia Capitoli (3), Silvia Tettamanti (1), Vanna Denti (1), Andrew Smith (1), Clizia Chinello (1), Martina Stella (1), Davide Leni (4), Mattia Garancini (5), Stefania Galimberti (3), Fulvio Magni (1) and Fabio Pagni (2)
(1) University of Milano-Bicocca, Department of Medicine and Surgery, Clinical Proteomics and Metabolomics Unit, Italy (2) University of Milano-Bicocca, Department of Medicine and Surgery, Section of Pathology, Italy (3) University of Milano-Bicocca, Department of Medicine and Surgery, Centre of Biostatistics for Clinical Epidemiology, Italy (4) San Gerardo Hospital, Department of Radiology, Italy (5) San Gerardo Hospital, Department of Surgery, Italy


Thyroid lesions diagnosis is performed by image-guided fine needle aspiration biopsy (FNAB) regarded as a gold standard procedure. However, about 25% of FNABs are considered as “indeterminate for malignancy” and surgery is commonly recommended. Nevertheless, final histology highlight that 80% of them are benign lesions. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) enables to explore the spatial distribution of biomarkers directly on cytological specimens, by integrating molecular and morphological evidence. This study focus on the proteomic profile stability of cytological samples in well-known preservative solutions, in order to have a standard methodology for the proteomic MALDI-MSI analysis of thyroid FNABs.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: